ORBIMED ADVISORS LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-08 7:55 pm Unchanged |
2024-05-06 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 6,943,654 11.100% |
0 (Unchanged) |
Filing |
| 2021-11-03 3:03 pm Unchanged |
2021-11-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 6,943,654 14.900% |
0 (Unchanged) |
Filing |
| 2021-09-22 5:21 pm Sale |
2021-09-20 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 6,943,654 16.400% |
-1,109,644 (-13.78%) |
Filing |
| 2021-08-04 5:21 pm Unchanged |
2021-08-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 8,053,298 19.000% |
0 (Unchanged) |
Filing |
| 2021-02-17 5:08 pm Purchase |
2021-02-17 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 8,053,298 21.980% |
1,285,714 (+19.00%) |
Filing |